Am J Psychiatry 161:532-538, March 2004
© 2004 American Psychiatric Association
Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer’s Disease
Jeffrey L. Cummings, M.D.,
Lon Schneider, M.D.,
Pierre N. Tariot, M.D.,
Paul R. Kershaw, M.D., and
Weiying Yuan, Ph.D.
OBJECTIVE: Alzheimer’s disease pathology includes both histologic changes and neurotransmitter deficits. The cholinergic deficit contributes to both cognitive and behavioral disturbances, and cholinesterase inhibitors may improve behavior in Alzheimer’s disease patients. This analysis was conducted to assess the impact of galantamine, a cholinesterase inhibitor with nicotinic-receptor-modulating properties, on the pattern and evolution of behavioral disturbances in patients with Alzheimer’s disease and on caregiver distress related to patients’ behavior. METHOD: Data from 978 patients with mild to moderate Alzheimer’s disease who were randomly assigned to placebo or galantamine (8, 16, or 24 mg/day) were analyzed. Behavioral changes were assessed with the Neuropsychiatric Inventory, and alterations in caregiver distress were measured by the Neuropsychiatric Inventory distress scale. Data collected at baseline and 12 and 21 weeks postbaseline were analyzed. RESULTS: Neuropsychiatric Inventory scores worsened with placebo, whereas patients treated with 16 or 24 mg/day of galantamine had no change in total Neurospcyhiatric Inventory scores. Treated patients, asymptomatic or symptomatic at baseline, had better Neuropsychiatric Inventory subscale scores than did patients receiving placebo. Behavioral improvement in patients symptomatic at baseline ranged from 29% to 48%. Changes were evident in patients receiving 16 or 24 mg/day of galantamine. High-dose galantamine was associated with a significant reduction in caregiver distress. CONCLUSIONS: Galantamine therapy was associated with reduced emergence of behavioral disturbances and improvement in existing behavioral problems in patients with mild to moderate Alzheimer’s disease, with a concomitant reduction in reported caregiver distress.
This article has been cited by other articles:
|
|
|
|
 
P. H. Lu, S. D. Edland, E. Teng, K. Tingus, R. C. Petersen, J. L. Cummings, and On behalf of The Alzheimer's Disease Cooperative S
Donepezil delays progression to AD in MCI subjects with depressive symptoms
Neurology,
June 16, 2009;
72(24):
2115 - 2121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Schoenmakers, F. Buntinx, and J. De Lepeleire
Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver?
Fam. Pract.,
May 7, 2009;
(2009)
cmp024v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tangwongchai, N. Thavichachart, V. Senanarong, N. Poungvarin, K. Phanthumchinda, R. Praditsuwan, S. Nidhinandana, and S. Chankrachang
Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer's Disease With or Without Cerebrovascular Disease
American Journal of Alzheimer's Disease and Other Dementias,
January 1, 2009;
23(6):
593 - 601.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Chan, J. Paskavitz, R. Remington, S. Rasmussen, and T. B. Shea
Efficacy of a Vitamin/Nutriceutical Formulation for Early-stage Alzheimer's Disease: A 1-year, Open-label Pilot Study With an 16-Month Caregiver Extension
American Journal of Alzheimer's Disease and Other Dementias,
January 1, 2009;
23(6):
571 - 585.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J. Howard, E. Juszczak, C. G. Ballard, P. Bentham, R. G. Brown, R. Bullock, A. S. Burns, C. Holmes, R. Jacoby, T. Johnson, et al.
Donepezil for the Treatment of Agitation in Alzheimer's Disease
N. Engl. J. Med.,
October 4, 2007;
357(14):
1382 - 1392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Swanson and R. M. Carnahan
Dementia and Comorbidities: An Overview of Diagnosis and Management
Journal of Pharmacy Practice,
August 1, 2007;
20(4):
296 - 317.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. T. Blaszczyk and M. Mathys
Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Journal of Pharmacy Practice,
February 1, 2007;
20(1):
13 - 28.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. A. Ally, G. E. Jones, J. A. Cole, and A. E. Budson
Sensory Gating in Patients With Alzheimer's Disease and Their Biological Children
American Journal of Alzheimer's Disease and Other Dementias,
January 1, 2007;
21(6):
439 - 447.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Bibliography PSYCHOPHARMACOLOGY
Focus,
September 1, 2006;
4(4):
512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings, E. Schneider, P. N. Tariot, S. M. Graham, and for the Memantine MEM-MD-02 Study Group
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Neurology,
July 11, 2006;
67(1):
57 - 63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Koontz and A. Baskys
Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: A double-blind placebo-controlled study
American Journal of Alzheimer's Disease and Other Dementias,
September 1, 2005;
20(5):
295 - 302.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Med.,
July 1, 2004;
9(4):
127 - 128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted: 06 Feb 2004 to 16 Apr 2004
Evid. Based Nurs.,
July 1, 2004;
7(3):
e3 - e3.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Galantamine for Behavioral Disturbances of AD
Journal Watch Women's Health,
May 25, 2004;
2004(525):
9 - 9.
[Full Text]
|
|
|
|
|
|
|
Galantamine May Improve Alzheimer Patients' Behavior and Caregiver Distress
Journal Watch Neurology,
May 7, 2004;
2004(507):
3 - 3.
[Full Text]
|
|
|
|
|
|
|
Galantamine May Improve Alzheimer Patients' Behavior and Caregivers' Distress
Journal Watch Psychiatry,
April 7, 2004;
2004(407):
4 - 4.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
